Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plenadren vs conventional hydrocortisone in central adrenal insufficiency
2013-004028-12Phase 4Active
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of hydrocortisone in central adrenal insufficiency (CAI) and hypoadrenocorticism (2 arms), sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoint: Medium-term metabolic and quality of life effects of Plenadren. Started Jan 2014; status: active.
02
Drugs
hydrocortisone
03
Conditions
central adrenal insufficiency (CAI)hypoadrenocorticism
Beyond the preview
Go deeper on 2013-004028-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004028-12.